Xilio Therapeutics Inc
Research Xilio Therapeutics Inc (XLO) on Bullrun: market cap USD 59.75M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXLO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 59.75M
- Financial periodQ1 2026
- RevenueUSD 12.65M
- Net income-USD 31.30M
- Free cash flow-USD 57.37M
Valuation Snapshot
latest market cap is USD 59.75M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 43.77M | -USD 35.04M | -USD 5.51M | n/a | -4.19 | USD 137.53M | USD 6.95M | USD 35.27M |
| FY2024 | USD 6.34M | -USD 58.24M | -USD 18.41M | n/a | -15.24 | USD 55.29M | USD 8.14M | USD 17.60M |
| FY2023 | n/a | -USD 76.40M | -USD 69.11M | n/a | -2.78 | USD 44.70M | USD 14.39M | USD 36.83M |
| FY2022 | n/a | -USD 88.22M | -USD 77.59M | n/a | -3.22 | USD 120.39M | USD 20.25M | USD 105.65M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 59.75M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 568.32M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 43.70M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 15.15M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 73.90M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 437.74M | n/a | n/a | n/a |
About Xilio Therapeutics Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xilio Therapeutics Inc's market cap?
Xilio Therapeutics Inc's market capitalization is USD 59.75M.
What does Xilio Therapeutics Inc do?
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.